eligibility_summary
Eligible: adults with histologically confirmed DLBCL, sGA-defined unfit/frail octogenarians or 60–79, non-GCB subtype, ECOG 0–3, no prior lymphoma therapy (except steroids), measurable disease (LN >1.5 cm or extranodal >1.0 cm), adequate organ function, life expectancy ≥12 wks, consent. Exclude: uncontrolled comorbidities, major lab/coag/hepatic/renal abnormalities, HIV, HBV DNA+, need for strong/moderate CYP3A inhibitors/inducers, cannot swallow/absorb, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial in frail elderly, treatment‑naive non‑GCB DLBCL tests PRO: polatuzumab vedotin + rituximab + orelabrutinib. Polatuzumab vedotin is an antibody–drug conjugate targeting CD79b that delivers MMAE to disrupt microtubules, inducing apoptosis in CD79b+ malignant B cells. Rituximab is a chimeric anti‑CD20 monoclonal antibody that depletes B cells via ADCC, CDC, and direct apoptosis. Orelabrutinib is an oral, covalent small‑molecule BTK inhibitor that blocks B‑cell receptor signaling, suppressing downstream NF‑κB survival pathways. Targeted cells/pathways: malignant B cells expressing CD79b and CD20, BCR pathway components (CD79b/BTK) and microtubules. Primary endpoint: complete response after induction.